Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva Buys Japanese Generics Company For $460 Mil.

This article was originally published in PharmAsia News

Executive Summary

Teva Pharmaceutical Industries Ltd. announced May 16 that it is acquiring more than half of Japan's third largest generic drugmaker and extending an offer to purchase the remaining portion of the company

You may also be interested in...



After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori

After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

MUMBAI - After years of desire to be in the Japanese generics drugs business, Dr. Reddy's Laboratories Ltd. CEO G.V. Prasad reached that milestone in the signing of a memorandum of understanding with Fujifilm Corp. CEO Shigetaka Komori

After Years Of Partner Search, India's Dr. Reddy's Forms JV With Fujifilm To Tap Japanese Generics Market

Although it surprised many in India to have Fujifilm's name associated with generic drugs, its penchant to explore the Japanese market coincides with the Japanese government's mission to encourage use of generic substitutes in Japan to drive costs down.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC077941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel